The lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas

Manuel Guix1,2, Anna Colomer1, Nadina Erill1, M. Assumpció Cañadas2, Ruth Román1, Xavier Puig1,2, Carlos Cordón-Cardó3.

1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied 100 primary colorectal […]


Activated Epidermal Growth Factor Receptor: Studies in head and neck tumors and tumor cell lines after exposure to ligand and receptor tirosine-kinase inhibitors

J. Baselga, M.A. Cañadas, J. Codony, J.A. Hueto, A. Arcas, A. Lladó, X. Puig, M. Guix, G. Raspall, J. Albanell.

The epidermal growth factor receptor (EGFr) is frequently overexpressed in head and neck tumors. Therapeutic strategies directed at preventing or reversing activation of the EGFr are being studied in the clinic. In this setting, assays to determinate the level of EGRr activation prior and during therapy could be instrumental to find the optimal biological dose of anti-receptor therapies. We have studied […]